Why the study?
Clinical use of doxorubicin is limited by strong side effects and cell resistance, which binding to nanoparticles may overcome, motivating exploration of DOX-loaded ZnO nanorods.
Does doxorubicin-loaded ZnO nanorods improve antitumor efficacy in resistant leukemia cancer cells compared to free doxorubicin?
Does doxorubicin-loaded ZnO nanorods improve antitumor efficacy in resistant leukemia cancer cells compared to free doxorubicin?
Doxorubicin-loaded ZnO nanorods demonstrate enhanced in vitro cytotoxicity against resistant leukemia cells compared to free doxorubicin, suggesting a potential strategy to overcome drug resistance.
May support nanocarrier strategies against resistant leukemia; leaves open clinical translation from animal data.
The clinical use of the anticancer drug doxorubicin (DOX) is limited by strong side effects and phenomena of cell resistance. Drug targeting by binding DOX to nanoparticles could overcome these limitations. We recently described a method to associate DOX to ZnO nanorods with average size of 21×200 nm. DOX is bound to the nanoparticle surface through a pre-formed folic acid-SiO2@ZnO conjugate. Characterization of the prepared samples was carried out using Fourier Transform infra-red spectra (FTIR) and UV-Visible spectroscopy. The purpose of this study is to explore the possible mechanisms of the in vitro cytotoxicity of DOX-loaded ZnO nanorods. The potential of anticancer drug (doxorubicin) loaded on the as prepared nanoparticles against the resistant leukemia cancer cells, K562, was evaluated using the MTT assay and its antitumor efficacy of the drug-loaded NRs was clearly enhanced, compared with free drugs.
No takes yet. Share an insight, caveat, or question.
Sabah et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: